(Q90072409)

English

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

scientific article published on 12 September 2019

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

metastatic adenocarcinoma

1 reference

based on heuristic

inferred from title

author name string

Philip A Philip

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Marc E Buyse

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Angela T Alistar

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Caio MSPR Rocha Lima

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Sanjeev Luther

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Timothy S Pardee

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Eric Van Cutsem

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

publication date

12 September 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Future Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

3189-3196

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The method of minimization for allocation to clinical trials. a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic Adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autophagy sustains pancreatic cancer growth through both cell autonomous and non-autonomous mechanisms.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy and radiotherapy for advanced pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic Dependencies in Pancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/31512497

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2217/FON-2019-0209

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31512497%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q90072409&oldid=1528574517"